THE WATTS GROUP PLLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$640K

Filings

Unique Clients

Active Period

2018–2020

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2020	$280,000	5	2
2019	$240,000	6	3
2018	$120,000	3	1

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
JUUL LABS, INC	$280,000	6	2019–2020
NOVARTIS	$180,000	4	2019–2020
SHIRE PHARMACEUTICALS LLC	$180,000	4	2018–2019

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	10
SENATE	10

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	13
Medicare/Medicaid	Medicare/Medicaid	8
Science/Technology	Science/Technology	5
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	5
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	3
Tobacco	Tobacco	1

Bills Explicitly Cited (24)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2411116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258, Tobacco to 21 Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2411

S. 1258116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258, Tobacco to 21 Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 1258

H.R. 3116th Congress

Elijah E. Cummings Lower Drug Costs Now Act

2019 · fourth_quarter · Client: NOVARTIS

Open original LDA filing ↗

Cited source text and reported amounts

Medical innovation, gene therapy, health care costs, newborn screening saves lives reauthorization. S. 2543; H.R. 3.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 3

S. 2543116th Congress

Prescription Drug Pricing Reduction Act of 2019

2019 · fourth_quarter · Client: NOVARTIS

Open original LDA filing ↗

Cited source text and reported amounts

Medical innovation, gene therapy, health care costs, newborn screening saves lives reauthorization. S. 2543; H.R. 3.

Client expense: — · Firm income: $60,000

Matched citations: S. 2543

Show 20 more cited filings

H.R. 2411116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: H.R. 2411

H.R. 2411116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: H.R. 2411

H.R. 2411116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: H.R. 2411

H.R. 2411116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: H.R. 2411

S. 1258116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: S. 1258

S. 1258116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: S. 1258

S. 1258116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: S. 1258

S. 1258116th Congress

Tobacco to 21 Act

2019 · fourth_quarter · Client: JUUL LABS, INC

Open original LDA filing ↗

Cited source text and reported amounts

Regulation of e-cigarettes and vaping products designed to improve the lives of adult smokers. Support proposals to prohibit the sale of tobacco or vaping products to individuals under the age of 21. H.R. 2411/S. 1258.

Client expense: — · Firm income: —

Matched citations: S. 1258

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

H.R. 4274115th Congress

Higher Education Reform and Opportunity Act of 2017

2018 · fourth_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4274, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4274

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · fourth_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4274, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: H.R. 4724

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Client: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: S. 1194

Source: Senate LDA

THE WATTS GROUP PLLC — Lobbying Disclosure | Poliscope